Back to today’s briefing

Story perspectives

Exenatide Fails to Benefit Parkinson’s Patients in Study

2/5/2025

40 8

Summary

Story summary

The Exenatide-PD3 study, led by Professor Tom Foltynie, revealed disappointing results as the diabetes drug exenatide showed no significant benefits for Parkinson’s patients compared to a placebo. Published in The Lancet, these findings spark a renewed quest to understand the potential of GLP-1R agonists in treating this challenging disease.

1 of 1

Story summary

The Exenatide-PD3 study, led by Professor Tom Foltynie, revealed disappointing results as the diabetes drug exenatide showed no significant benefits for Parkinson’s patients compared to a placebo. Published in The Lancet, these findings spark a renewed quest to understand the potential of GLP-1R agonists in treating this challenging disease.